PolyPid
$ 3.74
-27.38%
21 Jul - close price
- Market Cap 98,747,000 USD
- Current Price $ 3.74
- High / Low $ 4.84 / 3.72
- Stock P/E N/A
- Book Value 0.46
- EPS -1.66
- Next Earning Report 2026-08-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.15 %
- ROE -7.59 %
- 52 Week High 5.73
- 52 Week Low 3.06
About
PolyPid Ltd., an advanced stage biopharmaceutical company, develops, manufactures and markets products based on the Polymer Lipid Encapsulation Matrix (PLEX) platform to address unmet medical needs. The company is headquartered in Petah Tikva, Israel.
Analyst Target Price
$12.25
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-02-11 | 2025-11-12 | 2025-08-13 | 2025-05-14 | 2025-02-12 | 2024-11-13 | 2024-08-14 | 2024-05-08 | 2024-02-14 | 2023-11-08 | 2023-08-09 |
| Reported EPS | -0.35 | -0.41 | -0.37 | -0.78 | -0.7 | -1.07 | -1.22 | -1.25 | -1.37 | -3.84 | -3.4 | -10.8 |
| Estimated EPS | -0.43 | -0.33 | -0.52 | -0.55 | -0.82 | -0.88 | -1 | -1.3 | -1.41 | -4.29 | -4.43 | -13.32 |
| Surprise | 0.08 | -0.08 | 0.15 | -0.23 | 0.12 | -0.19 | -0.22 | 0.05 | 0.04 | 0.45 | 1.03 | 2.52 |
| Surprise Percentage | 18.6047% | -24.2424% | 28.8462% | -41.8182% | 14.6341% | -21.5909% | -22% | 3.8462% | 2.8369% | 10.4895% | 23.2506% | 18.9189% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-12 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.31 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PYPD
2026-07-21 21:09:40
Azurity Pharmaceuticals has partnered with PolyPid Ltd. to commercialize D-PLEX100 in the U.S. and Canada for preventing abdominal colorectal surgical site infections. D-PLEX100, which provides localized, prolonged antibacterial activity, has shown positive results in clinical trials and received Breakthrough Therapy Designation from the FDA. The collaboration also includes exploring label expansion for additional surgical site infection indications.
2026-07-21 12:09:40
PolyPid has announced an exclusive commercial partnership with Azurity Pharmaceuticals for the U.S. and Canadian commercialization of D-PLEX₁₀₀, a product designed to prevent surgical site infections. PolyPid could receive over $320 million in upfront and milestone payments, including $30 million upfront, plus tiered royalties. Azurity will also fund D-PLEX₁₀₀'s clinical development for potential label expansion, following positive Phase 3 SHIELD II trial results and PolyPid's recent NDA submission to the FDA.
2026-07-21 11:33:18
PolyPid and Azurity have signed a deal regarding a surgical site infection drug. The article also mentions PolyPid's recent activities, including completing a rolling NDA submission to the FDA for D-PLEX100, reporting Q1 2026 earnings, and presenting Phase 3 trial data demonstrating D-Plex100's efficacy.
2026-07-21 11:31:00
Israeli biotech PolyPid has signed a deal with Azurity Pharmaceuticals to commercialize its D-PLEX100 drug, aimed at preventing surgical site infections, in the U.S. and Canada. The agreement could bring PolyPid over $320 million, including an initial $15 million and potential milestone payments. PolyPid will also receive royalties upon commercialization and retain global rights to the drug outside North America.
2026-07-21 11:30:18
PolyPid has announced an exclusive partnership with Azurity Pharmaceuticals for the commercialization of D-PLEX₁₀₀ in the U.S. and Canada for the prevention of surgical site infections. PolyPid stands to receive over $320 million in upfront and milestone payments, including $30 million upfront, plus tiered royalties. The agreement also includes Azurity funding clinical development for potential label expansion of D-PLEX₁₀₀ beyond current SSI indications, leveraging PolyPid's recent positive Phase 3 SHIELD II results and NDA submission.
2026-07-21 11:30:18
PolyPid has entered into an exclusive commercial partnership with Azurity Pharmaceuticals for its D-PLEX100 product in the U.S. and Canada, aimed at preventing surgical site infections. The deal, valued at over $320 million, includes upfront payments, milestones, and royalties, building on positive Phase 3 SHIELD II data showing a 60% reduction in infection risk. This partnership positions PolyPid for commercialization while retaining global rights outside North America and ownership of its core technology platforms.
